



PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice

Chen-Chen Sun^a, Chen-Yu Zhang^a, Jia-Xi Duan^b, Xin-Xin Guan^a, Hui-Hui Yang^a, Hui-Ling Jiang^a, Bruce D. Hammock^c, Sung Hee Hwang^c, Yong Zhou^a, Cha-Xiang Guan^a, Shao-Kun Liu^{b,*}, Jun Zhang^{d,**}

^a Department of Physiology, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, China

^b Department of Respiratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China

^c Department of Entomology and Nematology and UC Davis Comprehensive Cancer Center, University of California, Davis, CA 95616, USA

^d Department of Physiology, Hunan University of Medicine, Huaihua, Hunan 418000, China

ARTICLE INFO

Article history:

Received 4 December 2019

Accepted 31 December 2019

Available online 20 January 2020

Keywords:

Non-alcoholic fatty liver disease

Cyclooxygenase-2

Soluble epoxide hydrolase

PTUPB

NLRP3 inflammasome

ABSTRACT

Non-alcoholic fatty liver disease (NAFLD) affects 25% of the global adult population, and no effective pharmacological treatment has been found. Products of arachidonic acid metabolism have been developed into a novel therapy for metabolic syndrome and diabetes. It has been demonstrated that protective actions of a novel dual cyclooxygenase-2 (COX-2) and soluble epoxide hydrolase (sEH) inhibitor, PTUPB, on the metabolic abnormalities. Here, we investigated the effects of PTUPB on hepatic steatosis in high-fat diet (HFD)-induced obese mice, as well as in hepatocytes *in vitro*. We found that PTUPB treatment reduced body weight, liver weight, liver triglyceride and cholesterol content, and the expression of lipolytic/lipogenic and lipid uptake related genes (*Acc*, *Cd36*, and *Cidec*) in HFD mice. In addition, PTUPB treatment arrested fibrotic progression with a decrease of collagen deposition and expression of *Col1a1*, *Col1a3*, and α -SMA. *In vitro*, PTUPB decreased palmitic acid-induced lipid deposition and downregulation of lipolytic/lipogenic genes (*Acc* and *Cd36*) in hepatocytes. Additionally, we found that PTUPB reduced the production of pro-inflammatory cytokines and suppressed the NLRP3 inflammasome activation in HFD mice and hepatocytes. In conclusion, dual inhibition of COX-2/sEH attenuates hepatic steatosis by inhibiting the NLRP3 inflammasome activation. PTUPB might be a promising potential therapy for liver steatosis associated with obesity.

© 2020 Elsevier Inc. All rights reserved.

1. Introduction

Non-alcoholic fatty liver disease (NAFLD), featured by excessive triglyceride accumulation, affects 25% of the global adult population, and the prevalence keeps rising on all continents [1]. NAFLD ranges from simple hepatic lipid accumulation (hepatic steatosis) to non-alcoholic steatohepatitis (NASH) and then leads to hepatocellular carcinoma [2]. NAFLD is strongly associated with arterial hypertension, obesity, insulin resistance, and other obesity-related

metabolic disorders [3,4]. Currently, because the pathogenesis of NAFLD remains unclear, there is no approved pharmacological therapy available for the treatment of this epidemic disease.

Numerous studies show that sterile inflammation is a key trigger for the process of NAFLD [5,6]. NAFLD is associated with massive release of pro-inflammatory mediators, including tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), and IL-1 β [7]. It has been reported that mild-to-moderate lobular inflammatory cell infiltration was exhibited in the liver tissue of NAFLD rats induced by a high-fat diet (HFD) [8]. The NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome drives the sterile inflammation and plays a vital role in the development of NAFLD [9]. Activation of the NLRP3 inflammasome, which can sense a wide range of danger signals, activates caspase-1 and results in the maturation and release of pro-inflammatory cytokines, such as IL-1 β and IL-18 [10]. The excessive increase of IL-1 β and IL-18

* Corresponding author. The Second Xiangya Hospital, Central South University, Hunan 410011, China.

** Corresponding author. Hunan University of Medicine Huaihua, Hunan 418000, China.

E-mail addresses: shaokunliu228@csu.edu.cn (S.-K. Liu), hhyzzj1314@126.com (J. Zhang).

aggravates inflammatory cytokines production and leads to hepatic steatosis and metabolic disorders [11].

The metabolites of arachidonic acid (ARA), which is an abundant lipid mediator in the body, have many different biological functions [12]. Product of ARA metabolism has been developed into a novel therapy for metabolic syndrome and diabetes [13,14]. Cyclooxygenase-2 (COX-2) is up-regulated in patients or animal models with metabolic syndrome, resulting in accumulation of prostaglandins (PGs) [15,16]. Accordingly, COX-2 inhibition decreases metabolic syndrome of the kidney in animal models [17]. Epoxyeicosatrienoic acids (EETs), which generate from the ARA by cytochrome P450 (CYP), have anti-inflammatory biological activities [18,19]. The activity of EETs can be enhanced by blocking their metabolism by soluble epoxide hydrolase (sEH) [20]. Recent research indicates that inhibition of any of the biosynthetic pathway of ARA could switch to the other, leading to fatal side effects [21]. So, we developed a novel dual COX-2/sEH inhibitor, PTUPB [22]. We have reported that the protective actions of this novel dual COX-2/sEH inhibitor on the metabolic abnormalities [23] and pulmonary fibrosis [12]. However, it still unclear whether the dual inhibition of COX-2/sEH has a beneficial action on NAFLD induced by HFD.

Given the anti-inflammatory and anti-metabolic abnormalities effects of dual inhibition of COX-2/sEH and the current limitations in the treatment of NAFLD, we tested the hypothesis that the protective effects of simultaneous inhibition of COX-2 and sEH by PTUPB against HFD-induced NAFLD.

2. Materials and methods

2.1. Animals experiments

All experiments were approved by the Ethics Committee of Clinical Medicine Research Institute of Central South University (Changsha, China). Adult male C57BL/6 mice (20 ± 2 g) were purchased from Hunan SJA Laboratory Animal Co., Ltd (Hunan, China). All animals were housed in a specific pathogen-free environment and exposed to a 12-h light/dark cycle, with free access to water and a normal diet for one week. Then mice were randomly divided into four groups: the control group (received normal diet), HFD group (received HFD with 60% calories), PTUPB group (5 mg/kg, *s.c.*, daily), and HFD + PTUPB group (received HFD and PTUPB, 5 mg/kg, *s.c.*, daily). Mice were weighed every week. Twelve weeks later, mice were sacrificed, and livers were collected and weighted (Fig. 1A).

2.2. Hepatocellular damage assay

Blood samples were isolated. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity, indicators of hepatocellular injury, were measured using the automatic biochemical analyzer (Hitachi automatic biochemical analyzer 7000, Japan).

2.3. Histological analysis

For morphometric studies, liver tissues were fixed in 4% paraformaldehyde solution and embedded in paraffin and cut into 4- μ m thick sections. Sections were stained with H&E to observe the tissue morphology or stained with Masson to assess the collagen deposition. Another part of the mouse liver tissue was embedded in the optimal cutting temperature compound (OCT) for Oil Red O staining.

2.4. Triglycerides measurement

Partially frozen mouse liver tissue was taken, weighed, and then physiological saline was added at 1:9. Grinding was carried out under ice bath conditions to prepare a homogenate. After centrifugation at 2500 rpm for 10 min, the supernatant was taken, and the triglyceride (TG) content of the mouse liver tissue was measured according to the TG assay kit (Jiancheng Bioengineering Institute, Nanjing, China).

2.5. Cell culture and treatment

The immortalized mouse normal hepatocyte cell line AML12 was cultured in DMEM/F12 media (Gibco, USA) containing 10% fetal bovine serum, Insulin-Transferrin-Selenium supplement (Gibco, USA), and 40 ng/mL dexamethasone, at 37 °C with 5% CO₂. To investigate the effects of PTUPB on the hepatosteatosis of AML12 cells, we pretreated cells with PTUPB (1 μ M) for 1 h according to a previous study [12], followed by the treatment of palmitic acid (PA, 0.15 mM, and 0.2 mM) for another 12 h.

2.6. Oil red O staining

Take out the frozen slices, re-warm at room temperature for 10 min, and then washed with distilled water for 3 min to remove the embedding agent. Cell samples were washed twice with PBS and then fixed with 4% paraformaldehyde for 40 min. The paraformaldehyde solution was discarded and washed twice with distilled water. After soaking for 2 min in 60% isopropanol, slices were stained with Oil Red O working solution (Sigma, USA) for 2 min. It was colored with 60% isopropanol, washed with water, then counterstained with hematoxylin and fixed.

2.7. Total RNA extraction and real-time PCR

Total RNA of mouse livers was extracted using Trizol Reagent (Invitrogen) according to the manufacturer's protocol. Then, the RNA was reverse transcribed into cDNA according to the reverse transcription system kit (Takara). Real-time PCR was implemented using SYBR Green (Takara) on the Bio-Rad real-time PCR system (CFX96 Touch™, Bio-Rad, USA). Gene expression levels were calculated by normalizing to β -actin by the $2^{-\Delta\Delta Ct}$ method. Primer sequences used in this study are listed in Table 1.

2.8. Western blot

As described in our previous study [24]. Frozen mouse liver tissue was taken out and lysed in cold RIPA buffer (Solarbio, Beijing, China) containing a protease inhibitor (Roche, Mannheim, Germany). Protein quantification was performed using a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific), and the protein (30 mg) in each sample was separated by 12% SDS-PAGE, and then transferred to 0.45- μ m polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% fat-free milk and incubated with the primary antibodies overnight at 4 °C. Subsequently, membranes were incubated with appropriate secondary HRP-linked antibodies. The proteins were detected with a gel imaging system (Bio-Rad). The antibodies used in present research were as follows: rabbit *anti*-COX-2 antibody (1:1000, Servicebio, Wuhan, China), rabbit *anti*-sEH antibody (1:5000, Abcam, USA), rabbit *anti*- β -tubulin antibody (1:2000, Servicebio), rabbit *anti*- α -SMA antibody (1:1000, SAB, Maryland, USA), rabbit *anti*-NLRP3 antibody (1:2000, CST, USA), rabbit *anti*-pro-caspase-1 antibody (1:1000, Abcam). The expression of protein was normalized to β -tubulin.

2.9. Statistical analysis

Data are expressed as the mean \pm SD of three independent experiments. Statistical analysis was processed by GraphPad Prism 7.0 software (San Diego, CA, USA) or SPSS 22.0 (IBM, Chicago, IL). Unpaired *t*-tests were used between the two groups for comparison. The statistical comparisons among the multiple groups were assessed with ANOVA. Tukey's test was used as a post hoc test to make pair-wise comparisons. *P*-value < 0.05 was considered statistically significant.

3. Results

3.1. COX-2 and sEH expression are increased in the liver of NAFLD mice

Firstly, we analyzed COX-2 and sEH protein expression in the liver of the HFD-treated mice. We found that both COX-2 and sEH levels in livers of the NAFLD mice were higher than that in the control group (Fig. 1B–C), indicating that dysregulation of ARA metabolism participates in the development of NAFLD. While, treatment with PTUPB significantly reduced COX-2 and sEH protein expression (Fig. 1B–C). These results suggest an important role of liver-expressed COX-2 and sEH dysregulation in the development of NAFLD in mice.

3.2. PTUPB ameliorates HFD-induced NAFLD and fibrosis in mice

Next, we examined whether the dual COX-2 and sEH inhibition had beneficial effects on liver steatosis in an HFD-induced obesity mice model. We found the administration of PTUPB significantly decreased the weight gain compared to the HFD group from the 4th to 12th week (Fig. 2A–D). Oil Red O staining and TG content indicated that PTUPB administration ameliorated hepatosteatosis in HFD mice (Fig. 2E–F). PTUPB lowered the serum ALT and AST levels in the HFD mice, indicating an attenuated liver injury (Fig. 2G–H). Importantly, we detected lipolytic/lipogenic and lipid uptake-related genes, including the key fatty acid synthesis enzyme (*acetyl-CoA carboxylase, Acc*), lipid uptake gene (*cluster of differentiation 36, Cd36*), and lipid droplet marker (*cell death-*




Fig. 1. COX-2 and sEH expression are increased in the liver of NAFLD mice. (A) C57BL/6 mice were fed with HFD with or without subcutaneous injection of PTUPB (5 mg/kg) for 12 weeks. (B–C) COX-2 and sEH protein expressions in liver tissue were detected using western blot. Data are shown as the mean \pm SD (*n* = 8). **P* < 0.05 and ***P* < 0.01.

inducing DFF45-like effector C, Cidec). We found that PTUPB exhibited an apparent inhibitory effect on these genes (Fig. 2I). In parallel, fibrotic genes (*Col1a1* and *Col3a1*) detection (Fig. 2I), Sirius red staining (Fig. 2J), and α -SMA detection (Fig. 2K) revealed that PTUPB treatment ameliorated the degree of liver fibrosis in the HFD mice. Overall, these data indicate that dual COX-2/sEH inhibition relieves liver steatosis and fibrosis in HFD-induced NAFLD mice.

3.3. PTUPB attenuates the NLRP3 inflammasome activation of HFD-fed mice

Inflammation can exacerbate the development of NAFLD [25]. As shown in Fig. 3A–B, the liver of the HFD group exhibited severe inflammatory cell infiltration, while PTUPB treatment remarkably decreased the inflammation score compared with that of the HFD group. Additionally, PTUPB reduced the mRNA expressions of pro-inflammatory factors, including *Tnf- α* , *Mcp-1*, and *Il-6* (Fig. 3C). Accumulating evidence suggests that the NLRP3 inflammasome regulates the maturation and release of IL-1 β and IL-18, and contributes to the development of NAFLD [7]. The mRNA expressions of *Nlrp3*, *Asc*, *pro-caspase-1*, *pro-Il-1 β* , and *pro-Il-18* in liver tissues of HFD mice were decreased after treatment with PTUPB (Fig. 3D). As expected, PTUPB significantly reduced the NLRP3, pro-caspase-1, and caspase-1 p10 protein expression (Fig. 3E). These results indicate that PTUPB exerts an anti-inflammatory effect against HFD-induced inflammation in mice, maybe via inhibiting the NLRP3 inflammasome activation.

3.4. PTUPB alleviates hepatosteatosis in a mouse hepatic cell line in vitro

To affirm the observation *in vivo*, we treated hepatocyte AML12 cells with PA for 12 h. We found that PTUPB significantly reduced *Cox-2* mRNA expression induced by PA treatment (Fig. 4A). PTUPB also remarkably decreased PA-induced lipid deposition in AML12 cells, as revealed by Oil red O staining (Fig. 4B). PA-induced upregulation of lipolytic/lipogenic and lipid uptake-related genes (*Acc* and *Cd36*) and inflammation-related genes (*Tnf- α* and *Il-6*) were suppressed by PTUPB administration in AML12 cells (Fig. 4C–D). Additionally, PTUPB reduced the mRNA levels of NLRP3

Table 1
Primer sequences used in this study.

| Gene | Forward primer (5'–3') | Reverse primer (5'–3') |
|-----------------------------------|--------------------------|------------------------|
| <i>Pparα</i> | gctcactgttttctggttgta | gactctgttttctggctcttc |
| <i>Acc</i> | tctcctccaactcaaccac | aagcagcccatcactctac |
| <i>Cd36</i> | gaaccactgctttcaaaaactgg | tgctgtctttgccagctca |
| <i>Cpt1a</i> | cgctactcctgaaagt | cttgaccataccatccag |
| <i>Fxr</i> | ggcagaatctggatttggaaatcg | gcccagttggaatagtaagacg |
| <i>Fas</i> | tgctgtggcctttgaaatgtgct | acacgctctctaggccttca |
| <i>Adrp</i> | gtggtctgagcaggcttcat | agggaagggaaaaactcacctc |
| <i>Cidec</i> | ggggagggtccaacacaatc | gggtacagaggctgagaga |
| <i>Apob</i> | aagaccatcctgagccagac | ggtctgttcttatgccagc |
| <i>Col1a1</i> | gagcggagagtactggatcg | gctcttttctctggggttc |
| <i>Col3a1</i> | gcacagcagtcacaactaga | cttccaatgggatctctgg |
| <i>Tnf-α</i> | agccccagctctgtatcctt | ctcccttgcagaactcagg |
| <i>Mcp-1</i> | gtcctgtcatgctctctgg | gcttgaactgcatctggct |
| <i>Il-6</i> | cgcccttccctacttcacaa | tgtgactccagctatctcttgg |
| <i>Nlrp3</i> | tacggcgtctactcttct | cgcatatcacactctcaaa |
| <i>Asc</i> | gacagtaccaggcagttctg | agctcttgcaggctcagttc |
| <i>pro-Il-1β</i> | caggcaggcagatctactca | agctcatatgggtccgacag |
| <i>pro-Il-18</i> | acgtgttccaggacacaaca | caaacctccccacttaact |
| <i>pro-caspase-1</i> | cacagctctggagatggtga | ctttcaagcttgggacattc |
| <i>Cox-2</i> | catccccctctgcgaagtt | catgggagttgggagctcat |
| β -actin | tccagcctctctcttctg | ggagccagagcagtaact |




Fig. 2. PTUPB ameliorates HFD-induced NAFLD and liver fibrosis in mice. (A) Representative images of mice fed with HFD with or without PTUPB. (B–D) The change of body weight and liver weight of mice after HFD treatment for 12 weeks with or without PTUPB. (E) Representative photomicrographs of liver sections stained with Oil Red O. Scale bars = 100 μ m. (F–H) Content of TG in liver tissue and activity of ALT and AST in the serum of mice. (I) The expression of lipolytic/lipogenic and lipid uptake-related genes (*Ppara*, *Acc*, *Cd36*, *Cpt1a*, *Fxr*, *Fas*, *Adrp*, *Cidec*, and *ApoB*) and fibrotic genes (*Col1a1* and *Col3a1*) in liver tissue were detected using real-time PCR. (J) Representative photomicrographs of liver sections stained with Masson's trichrome. Scale bars = 100 μ m. (K) α -SMA protein expression in liver tissue was detected using western blot. Data are shown as the mean \pm SD ($n = 8$). * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

inflammasome-associated genes (*Nlrp3*, *Asc*, *pro-caspase-1*, and *pro-IL-18*) induced by PA (Fig. 4E). These data strongly suggest an inhibitory role of PTUPB on hepatosteatosis and inflammation in mouse hepatocytes *in vitro*.

4. Discussion

In the present study, we explored new potential therapeutic effects of dual COX-2/sEH inhibition by PTUPB, which can ameliorate hepatic steatosis in obese mice. The *anti*-steatosis effects of PTUPB may result from the suppression of NLRP3 inflammasome activation. Our data indicate that dual inhibition of COX-2/sEH might be an effective treatment for obesity-associated hepatosteatosis associated with obesity.

PTUPB simultaneously acts on COX-2 and sEH pathways of ARA metabolism, which has many pharmacological activities, such as anti-cancer and anti-fibrosis [12,26]. It is reported that PTUPB inhibits allergen-induced airway inflammation by inhibiting eosinophilic infiltration and increasing levels of anti-inflammatory EETs in the lung tissue [27]. PTUPB also can attenuate kidney injury *via* reducing renal inflammation and oxidative stress in type 2 diabetic Zucker diabetic fatty rats [23]. NAFLD is commonly associated with metabolic comorbidities with no approved pharmacologic agents currently [2,28]. In this study, we reported that COX-2 and sEH levels were increased in the livers of NAFLD mice, as well as the expression of the lipolytic/lipogenic and lipid uptake related genes. ACC active produces malonyl-CoA, blocks the production of new fatty acids, and inhibits the transfer




Fig. 3. PTUPB attenuates liver inflammation and inhibits the NLRP3 inflammasome activation of HFD-fed mice. (A) Representative photomicrographs of liver sections stained with H&E. Scale bars = 100 μ m. (B) Inflammation score (based on H&E staining) expressed on a numerical scale. (C) *Tnf- α* , *Mcp-1*, and *Il-6* mRNA expression in liver tissue were detected using real-time PCR. (D) *Nlrp3*, *Asc*, *pro-caspase-1*, *pro-Il-1 β* , and *pro-Il-18* mRNA expression in liver tissue were detected using real-time PCR. (E) NLRP3, pro-caspase-1, and caspase-1 p10 protein expression in liver tissue were detected using western blot ($n = 8$). Data are shown as the mean \pm SD. * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.

of the fatty acyl group from acyl CoA to carnitine with carnitine acyltransferase [29]. CD36 contributes to intracellular lipid accumulation [30]. CIDEA participates in the differentiation of adipocyte adipogenesis [31]. Here, we found that PTUPB significantly reduced *Acc*, *Cd36*, and *Cidec* expression. Moreover, PTUPB treatment decreased the body weight, liver weight, and serum levels of TG of mice in the HFD group. In addition, the generation of liver fibrosis in NAFLD, which is a key feature of progressive disease [32]. Based on those findings, we proposed a new therapeutic potential for NAFLD.

Inflammation is considered vital pathogenesis of the majority of acute and chronic liver diseases, such as NAFLD and alcoholic fatty liver disease [25,33]. It has been pointed out that low-grade chronic inflammation of NAFLD is a link to hepatic lipid accumulation [34]. The inflammatory gene expression in the liver is increased in NAFLD mice, such as IL-1 β , IL-18, IL-6, and TNF- α [7,35]. Herein, we found that PTUPB suppressed the expression of pro-inflammatory cytokines in livers of NAFLD mice, including *Tnf- α* , *Mcp-1*, and *Il-6*. Accumulating evidence demonstrate that NLRP3 inflammasome is an indispensable contributor to the development of NAFLD

[36,37]. NLRP3 inflammasome, which is activated by metabolic danger signals, form the complex of the NLRP3 inflammasome by recruiting ASC together with pro-caspase-1, subsequently leading to cleaves pro-IL-1 β and pro-IL-18 into active forms [10]. In this study, we found that PTUPB treatment effectively suppressed the overexpression of NLRP3 and inhibited the activation of the NLRP3 inflammasome in the liver of HFD-fed mice. The *in vitro* study further confirmed that PTUPB could inhibit the activation of NLRP3 inflammasome in PA-treated hepatocyte. In other animal model, PTUPB also shows anti-inflammatory property. For example, PTUPB protects against allergen-induced bronchoconstriction and airway inflammation in asthma [27]. To the best knowledge of us, this is the first study indicating PTUPB could inhibit the activation of the NLRP3 inflammasome.

In conclusion, this study suggests that dual inhibition of COX-2/sEH attenuates hepatic steatosis by inhibiting the NLRP3 inflammasome activation *in vitro* and *in vivo*. And dual inhibition of COX-2/sEH might be a promising potential therapy for liver steatosis associated with obesity, though its potential in human disease remains unproven.




Fig. 4. PTUPB alleviates hepatoesteatosis in a mouse hepatic cell line *in vitro*. PTUPB (1 μ M) was added to PA (0.15 mM or 0.2 mM)-challenged AML12 cells. Twelve hours later, Cox-2 mRNA (A) in AML12 cells were determined using real-time PCR. (B) Representative photomicrographs of AML12 cells stained with Oil Red O. Scale bars = 100 μ m. (C) *Fxr*, *Fas*, *Acc*, and *Cd36* mRNA in AML12 cells were determined using real-time PCR. (D) *Tnf- α* and *Il-6* mRNA expression in AML12 cells were detected. (E) *Nlrp3*, *Asc*, *pro-caspase-1*, and *pro-Il-18* mRNA expression in AML12 cells were detected. Data are expressed as the mean \pm SD ($n = 5$). * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Data availability

The data used to support the findings of this study are available from the corresponding author upon request.

Author contributions

SKL and JZ conceived and designed the experiments. CCS, CYZ, JXD, XXG, and HHY performed the experiments. CCS, CYZ, and HLJ analyzed the data. BDH, JZ, and CXG contributed reagents/materials/analysis tools. HHS and BDH designed and synthesized PTUPB. CCS and YZ wrote the paper. CXG, SKL, and JZ critically reviewed the manuscript. All authors had final approval of the submitted versions.

Declaration of competing interest

The authors declare no competing financial interests.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (81670014), the Hunan Provincial Natural Science Foundation of China (2019JJ40453, 2016JJ6107), the Open Sharing Fund for the Large-scale Instruments and Equipments of Central South University (CSUZZC201944), and the Research Foundation of Education Bureau of Hunan Province, China (16A153).

References

- [1] T. Liu, X. Luo, Z.H. Li, J.C. Wu, S.Z. Luo, M.Y. Xu, Zinc-alpha2-glycoprotein 1 attenuates non-alcoholic fatty liver disease by negatively regulating tumour necrosis factor- α , *World J. Gastroenterol.* 25 (2019) 5451–5468.
- [2] B.Q. Starley, C.J. Calcagno, S.A. Harrison, Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection, *Hepatology* (Baltimore, Md 51 (2010) 1820–1832.
- [3] N. Chalasani, Z. Younossi, J.E. Lavine, M. Charlton, K. Cusi, M. Rinella, S.A. Harrison, E.M. Brunt, A.J. Sanyal, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, *Hepatology* 67 (2018) 328–357.
- [4] A.L. Birkenfeld, G.I. Shulman, Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes, *Hepatology* (Baltimore, Md 59 (2014) 713–723.
- [5] P. Kubesh, W.Z. Mehal, Sterile inflammation in the liver, *Gastroenterology* 143 (2012) 1158–1172.
- [6] Y. Lu, Z. Jiang, H. Dai, R. Miao, J. Shu, H. Gu, X. Liu, Z. Huang, G. Yang, A.F. Chen, H. Yuan, Y. Li, J. Cai, Hepatic leukocyte immunoglobulin-like receptor B4 (ILLRB4) attenuates nonalcoholic fatty liver disease via SHP1-TRAF6 pathway, *Hepatology* (Baltimore, Md 67 (2018) 1303–1319.
- [7] F. Wang, Y. Liu, J. Yuan, W. Yang, Z. Mo, Compound C protects mice from HFD-induced obesity and nonalcoholic fatty liver disease, *Int. J. Endocrinol.* 2019 (2019) 3206587.
- [8] S.H. El-Din, A.N. Sabra, O.A. Hammam, F.A. Ebeid, N.M. El-Lakkany, Pharmacological and antioxidant actions of garlic and/or onion in non-alcoholic fatty liver disease (NAFLD) in rats, *J. Egypt. Soc. Parasitol.* 44 (2014) 295–308.
- [9] K. Neumann, B. Schiller, G. Tiegs, NLRP3 inflammasome and IL-33: novel players in sterile liver inflammation, *Int. J. Mol. Sci.* 19 (2018). E2732.
- [10] T. Strowig, J. Henao-Mejia, E. Elinav, R. Flavell, Inflammasomes in health and disease, *Nature* 481 (2012) 278–286.
- [11] K. Schroder, J. Tschopp, The inflammasomes, *Cell* 140 (2010) 821–832.
- [12] C.Y. Zhang, J.X. Duan, H.H. Yang, C.C. Sun, W.J. Zhong, J.H. Tao, X.X. Guan, H.L. Jiang, B.D. Hammock, S.H. Hwang, Y. Zhou, C.X. Guan, COX-2/sEH dual inhibitor PTUPB alleviates bleomycin-induced pulmonary fibrosis in mice via inhibiting senescence, *FEBS J.* (2019).
- [13] G.H. Kim, Renal effects of prostaglandins and cyclooxygenase-2 inhibitors, *Electrolyte & blood pressure, Electrolyte Blood Press.* 6 (2008) 35–41.
- [14] J. He, C. Wang, Y. Zhu, D. Ai, Soluble epoxide hydrolase: a potential target for metabolic diseases, *J. Diabetes* 8 (2016) 305–313.
- [15] E. Vessieres, E.J. Belin de Chantemele, B. Toutain, A.L. Guihot, A. Jardel, L. Loufrani, D. Henrion, Cyclooxygenase-2 inhibition restored endothelium-mediated relaxation in old obese Zucker rat mesenteric arteries, *Front. Physiol.* 1 (2010) 145.
- [16] R.P. Robertson, The COX-2/PGE2/EP3/Gi/o/cAMP/GSIS pathway in the Islet: the beat goes on, *Diabetes* 66 (2017) 1464–1466.
- [17] J.D. Imig, X. Zhao, A. Dey, M. Shaw, CYP450, COX-2 and obesity related renal

- damage, *Toxicol. Mech. Methods* 15 (2005) 125–136.
- [18] Y. Zhou, T. Liu, J.X. Duan, P. Li, G.Y. Sun, Y.P. Liu, J. Zhang, L. Dong, K.S.S. Lee, B.D. Hammock, J.X. Jiang, C.X. Guan, Soluble epoxide hydrolase inhibitor attenuates lipopolysaccharide-induced acute lung injury and improves survival in mice, *Shock* 47 (2017) 638–645.
- [19] S. Zarriello, J.P. Tuazon, S. Corey, S. Schimmel, M. Rajani, A. Gorsky, D. Incontri, B.D. Hammock, C.V. Borlongan, Humble beginnings with big goals: small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders, *Prog. Neurobiol.* 172 (2019) 23–39.
- [20] H. Sun, P. Lee, C. Yan, N. Gao, J. Wang, X. Fan, F.S. Yu, Inhibition of soluble epoxide hydrolase 2 ameliorates diabetic keratopathy and impaired wound healing in mouse corneas, *Diabetes* 67 (2018) 1162–1172.
- [21] P. Jaismy Jacob, S.L. Manju, K.R. Ethiraj, G. Elias, Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: a structure-based approach, *Eur. J. Pharm. Sci.* 121 (2018) 356–381.
- [22] S.H. Hwang, K.M. Wagner, C. Morisseau, J.Y. Liu, H. Dong, A.T. Weckler, B.D. Hammock, Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase, *J. Med. Chem.* 54 (2011) 3037–3050.
- [23] M.A. Hye Khan, S.H. Hwang, A. Sharma, J.A. Corbett, B.D. Hammock, J.D. Imig, A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat, *Prostaglandins Other Lipid Mediat.* 125 (2016) 40–47.
- [24] W.J. Zhong, H.H. Yang, X.X. Guan, J.B. Xiong, C.C. Sun, C.Y. Zhang, X.Q. Luo, Y.F. Zhang, J. Zhang, J.X. Duan, Y. Zhou, C.X. Guan, Inhibition of glycolysis alleviates lipopolysaccharide-induced acute lung injury in a mouse model, *J. Cell. Physiol.* 234 (2019) 4641–4654.
- [25] H. Cortez-Pinto, M.C. de Moura, C.P. Day, Non-alcoholic steatohepatitis: from cell biology to clinical practice, *J. Hepatol.* 44 (2006) 197–208.
- [26] A. Gartung, J. Yang, V.P. Sukhatme, D.R. Bielenberg, D. Fernandes, J. Chang, B.A. Schmidt, S.H. Hwang, D. Zurakowski, S. Huang, M.W. Kieran, B.D. Hammock, D. Panigrahy, Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor, *Proc. Natl. Acad. Sci. U.S.A.* 116 (2019) 1698–1703.
- [27] K. Daham, A. James, D. Balgoma, M. Kupczyk, B. Billing, A. Lindeberg, E. Henriksson, G.A. FitzGerald, C.E. Wheelock, S.E. Dahlen, B. Dahlen, Effects of selective COX-2 inhibition on allergen-induced bronchoconstriction and airway inflammation in asthma, *J. Allergy Clin. Immunol.* 134 (2014) 306–313.
- [28] G.C. Farrell, C.Z. Larter, Nonalcoholic fatty liver disease: from steatosis to cirrhosis, *Hepatology* (Baltimore, Md) 43 (2006) S99–S112.
- [29] X.H. Xiao, Y.D. Wang, X.Y. Qi, Y.Y. Wang, J.Y. Li, H. Li, P.Y. Zhang, H.L. Liao, M.H. Li, Z.Z. Liao, J. Yang, C.X. Xu, G.B. Wen, J.H. Liu, Zinc alpha2 glycoprotein protects against obesity-induced hepatic steatosis, *Int. J. Obes.* 42 (2005) 1418–1430, 2018.
- [30] D. Sheng, S. Zhao, L. Gao, H. Zheng, W. Liu, J. Hou, Y. Jin, F. Ye, Q. Zhao, R. Li, N. Zhao, L. Zhang, Z. Han, L. Wei, BabaoDan attenuates high-fat diet-induced non-alcoholic fatty liver disease via activation of AMPK signaling, *Cell Biosci.* 9 (2019) 77.
- [31] C. Lebeaupin, D. Vallee, D. Rousseau, S. Patouraux, S. Bonnafous, G. Adam, F. Luciano, C. Luci, R. Anty, A. Iannelli, S. Marchetti, G. Kroemer, S. Lacas-Gervais, A. Tran, P. Gual, B. Bailly-Maitre, Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice, *Hepatology* (Baltimore, Md) 68 (2018) 515–532.
- [32] J.K. Dowman, J.W. Tomlinson, P.N. Newsome, Pathogenesis of non-alcoholic fatty liver disease, *QJM : Mon. J. Assoc. Phys.* 103 (2010) 71–83.
- [33] V. Racanelli, B. Rehermann, The liver as an immunological organ, *Gastroenterology* 43 (2004) S54–S62.
- [34] B. Xu, M.Z. Jiang, Y. Chu, W.J. Wang, D. Chen, X.W. Li, Z. Zhang, D. Zhang, D.M. Fan, Y.Z. Nie, F. Shao, K.C. Wu, J. Liang, Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice, *J. Hepatol.* 68 (2018) 773–782.
- [35] M. Feldmann, R.N. Maini, Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases, *Nat. Med.* 9 (2003) 1245–1250.
- [36] A. Wree, A. Eguchi, M.D. McGeough, C.A. Pena, C.D. Johnson, A. Canbay, H.M. Hoffman, A.E. Feldstein, NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice, *Hepatology* (Baltimore, Md) 59 (2014) 898–910.
- [37] J. Henao-Mejia, E. Elinav, C. Jin, L. Hao, W.Z. Mehal, T. Strowig, C.A. Thaiss, A.L. Kau, S.C. Eisenbarth, M.J. Jurczak, J.P. Camporez, G.I. Shulman, J.I. Gordon, H.M. Hoffman, R.A. Flavell, Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity, *Nature* 482 (2012) 179–185.